Venous thromboembolism prevention through the use of novel Factor Xa inhibitors.

Venous thromboembolism prevention through the use of novel Factor Xa inhibitors. Postgrad Med. 2018 Nov 03;: Authors: Al-Hillan A, Bajwa RS, Cheema A, Ezeume A, Gor S, Mahida H, Kountz DS Abstract The risk of a venous thromboembolic event is not limited to the pre-hospital, hospital, or immediate post-hospital period. Because of challenges with data collection, the risk of VTE up to 3 months post-hospitalization for patients with acute and serious medical problems in the setting of chronic disease and/or risk factors for venous thromboembolism (VTE) is probably under reported. The growing acceptance and indications of direct oral anticoagulants (DOACs) now includes an indication for VTE prevention for one of the Factor Xa agents. In this paper, the authors explore the issue of VTE in the extended post-hospital period and strategies to provide protection from these morbid and potentially mortal events with oral anticoagulants. PMID: 30394165 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research